These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21792211)

  • 1. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
    Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
    J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of liquid chromatography/tandem mass spectrometric molecular fingerprinting for the rapid structural identification of pharmaceutical impurities.
    Li M; Wang X; Chen B; Lin M; Buevich AV; Chan TM; Rustum AM
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3533-42. PubMed ID: 19844969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.
    Chen Y; Brill GM; Benz NJ; Leanna MR; Dhaon MK; Rasmussen M; Zhou CC; Bruzek JA; Bellettini JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):106-17. PubMed ID: 17826364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
    Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
    J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
    Thomas S; Paul SK; Shandilya S; Agarwal A; Saxena N; Awasthi AK; Matta Hb; Vir D; Mathela CS
    Analyst; 2012 Aug; 137(15):3571-82. PubMed ID: 22733388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
    J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.
    Schneider A; Wessjohann LA
    J Pharm Biomed Anal; 2010 Nov; 53(3):767-72. PubMed ID: 20570457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus.
    Boernsen KO; Egge-Jacobsen W; Inverardi B; Strom T; Streit F; Schiebel HM; Benet LZ; Christians U
    J Mass Spectrom; 2007 Jun; 42(6):793-802. PubMed ID: 17511017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis and evaluation of the impurity of felodipine and its tablets].
    Zhang N; Yu LJ; Li J; Tong JW; Meng J; Zhang QM; Shi YQ
    Yao Xue Xue Bao; 2012 Feb; 47(2):223-8. PubMed ID: 22512035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
    Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
    J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-line H/D exchange LC-MS strategy for structural elucidation of pharmaceutical impurities.
    Liu DQ; Wu L; Sun M; MacGregor PA
    J Pharm Biomed Anal; 2007 Jun; 44(2):320-9. PubMed ID: 17317074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of gentamicin impurities by liquid chromatography tandem mass spectrometry.
    Grahek R; Zupancic-Kralj L
    J Pharm Biomed Anal; 2009 Dec; 50(5):1037-43. PubMed ID: 19577403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LC-MS characterization of trace impurities contained in calcium folinate.
    Francese G; Corana F; Meneghetti O; Marazza F
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):757-63. PubMed ID: 15927438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.